AnthologyRX
Injection

Tesamorelin

Compounded tesamorelin centered on the molecule's studied visceral-fat pathway and the medical oversight it deserves.

Your treatment plan

From $159/month equivalent

$477 billed every 3 months3-month commitment$199 billed monthly also availableAll fees includedView plan details
Start assessment
  • Licensed clinicians
  • Compounded by a licensed 503A pharmacy
  • No clinic visit
Compare the GH peptidesImportant safety information

Questions before you start?

Compare this treatment

What will I pay?

Standard plan price$159 per month equivalent, billed $477 every 3 months. 3-month commitment.

Billing options and renewal

The standard Tesamorelin price is $199 billed monthly, or $477 paid up front every three months ($159 per month equivalent; a three-month commitment). These are recurring prices before any eligible first-order discount. A first-order offer reduces that order only; renewal uses the standard price for the chosen plan. A monthly equivalent is not a monthly charge.

View full plan details

What should I know about this treatment?

Compounded tesamorelin centered on the molecule's studied visceral-fat pathway and the medical oversight it deserves.

Read the evidence and its limitations

What should I review before starting?

A licensed clinician reviews your health history and medications and determines whether treatment is appropriate for you.

Read the full Important Safety Information

How do I request Tesamorelin online?

Complete the online assessment with your health history, current medications and treatment goals. A licensed clinician reviews the information and decides whether to prescribe. If prescribed, a licensed pharmacy prepares and ships your medication.

See how care works
What It Is

Not all abdominal fat is the same tissue.

Abdominal fat is not one uniform tissue. Subcutaneous fat sits beneath the skin. Visceral adipose tissue sits deeper in the abdomen, around the internal organs. The pivotal tesamorelin trials treated those as separate compartments and measured them separately with CT imaging.3

That specificity is the reason tesamorelin is interesting.

Tesamorelin is a growth hormone releasing factor analog. Rather than supplying growth hormone directly, it acts on the pituitary to stimulate the synthesis and pulsatile release of your own.4 The pivotal phase 3 program studied people who had developed excess visceral abdominal fat in the setting of antiretroviral therapy. The target was that fat accumulation, not HIV itself. Across both randomized placebo-controlled trials visceral adipose tissue decreased while abdominal subcutaneous fat did not change significantly.3

That distinction has appeared outside the original population as well. In a separate randomized, placebo-controlled trial of 60 adults with abdominal obesity and reduced growth hormone secretion, tesamorelin significantly reduced visceral adipose tissue while abdominal subcutaneous fat again did not change significantly.6 Same abdomen, different compartment, different result.

Specificity distinguishes this molecule. Tesamorelin is studied around visceral adipose tissue, not generic weight loss, and licensed-pharmacy sourcing plus clinician supervision separate the prescription from research-market vials.

  1. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor… J Clin Endocrinol Metab. 2010.DOI
  2. EGRIFTA WR (tesamorelin) for injection, for subcutaneous use. Full Prescribing Information. Theratechnologies Inc. Revised 03/2025.
  3. Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese… J Clin Endocrinol Metab. 2012.DOI
Read the evidence
Who It's For

For the case a clinician can define precisely.

01

The Visceral Fat Question

The concern is not simply a larger waist. Your clinician has a reason to think visceral adiposity belongs in the clinical picture, and can explain why tesamorelin is being considered.

02

The Metabolic Context

You want the conversation to go deeper than appearance. Your provider is looking at fat distribution alongside metabolic markers and the rest of your health rather than treating the mirror as the endpoint.

03

The Monitored Plan

You want treatment with clinical follow-through built in. Tesamorelin raises IGF-1 and can affect glucose tolerance, which is why both belong in the ongoing medical conversation.

Compounded tesamorelin is not an FDA-approved drug product. The FDA-approved tesamorelin medicine is indicated for reduction of excess abdominal fat in adults living with HIV who have lipodystrophy. The pivotal visceral fat figures on this page come from people with excess abdominal fat that developed in the setting of antiretroviral therapy, and tesamorelin was being studied to reduce that fat rather than to treat HIV. Those exact effect sizes should not be assumed to apply unchanged to every cause of visceral adiposity, though separate randomized research in adults with abdominal obesity and reduced growth hormone secretion has also shown a selective reduction in visceral adipose tissue. The approved labeling states that tesamorelin is not indicated for weight loss management and has a weight neutral effect. A licensed provider determines whether compounded tesamorelin fits your case, or whether another treatment serves you better.

This might not be the right fit if:
  • An active malignancy, or treatment for a previous malignancy that is not complete
  • Disruption of the hypothalamic-pituitary axis from pituitary disease, surgery, head irradiation or significant head trauma
  • Pregnancy or a planned pregnancy
  • A known hypersensitivity to tesamorelin
  • An acute critical illness

Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.

Your Plan

Tesamorelin, prescribed with care.

Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.

One price covers your consultation, provider review, medication if prescribed, pharmacy fulfillment, shipping and follow-up. All fees included.
Format
Injection
Strength
3 mg/mL
Total plan quantity
15 mL
Billed amount
$477 every 3 months
Monthly equivalent
$159 per month
Commitment
3 months
Monthly option
$199 billed monthly · 5 mL total plan quantity
Fees
Included in the plan price

Strength describes the preparation. Total plan quantity is the amount included in that plan, not your dose or dosing schedule. Follow the directions on your prescription.

Compare billing options and longer-term costs

Compounded by a licensed 503A pharmacy
Tesamorelin
Injection
From $159
Monthly equivalent. All fees included.

$477 billed every 3 months. 3-month commitment.

  • A subcutaneous injection, self-administered at home exactly as prescribed
  • Compounded by a licensed 503A pharmacy to your clinician’s specification
  • Glucose evaluated before treatment, with glucose and IGF-1 monitored during therapy
  • Injection sites rotated as directed to reduce site reactions
  • Reviewed and adjusted through your ongoing provider relationship
$159 /mo equivalent · 3-month commitment
$159/mo equivalent, all-in. Consultation is included in the plan price, not added on top. Consultation, cancellation and refund policy.
What happens when I start?

You'll begin an online assessment for Tesamorelin.

  1. Tell your clinician about you. Share your goals, health history and current medications.
  2. Review your plan. Confirm the treatment option, billing interval and total shown in the assessment.
  3. Get an individual clinical review. Your clinician decides whether to prescribe. If prescribed, a licensed pharmacy fulfills your prescription.

Starting an assessment doesn't guarantee a prescription. How care works

Start assessment

Prescription issued subject to provider judgment. Results vary. Not a guarantee of outcomes.

*Price reflects a 3-month commitment. See billing details above.

Your subscription renews at your selected billing interval. Cancel through your member dashboard before the next billing date to stop future charges. Cancellation does not refund the current billing period. See cancellation and refund terms.

Have a question about this plan?

Billing

Our support team can help with plan prices, billing and portal access.

Ask about billing

Shipping

Contact AnthologyRX support for help checking a shipment.

Get shipment help

Clinical questions

Message your provider about dosing, side effects, your response or changes in your health.

Open patient portal

New to AnthologyRX? Ask our team about getting started.

The people behind your care

Guidance from the first question onward.

Independent clinical care

Licensed clinicians affiliated with Arora Health & Aesthetics, LLC review your health history, medications and goals, then discuss whether Tesamorelin or another approach fits your needs.

Medical information on this page reviewed by Dr. Dylan Russell, MD, Chief Health Officer on . Your prescribing clinician provides your individual care.

Verify Dr. Russell's medical license

Pharmacy quality that matters

Prepared to your prescription by a licensed compounding pharmacy. Our partners have verified quality programs covering identity, potency, independent testing and batch documentation, with sterility and endotoxin controls for injectable preparations.

Compounded preparations are not FDA-approved. Pharmacy quality controls and your clinician's evaluation of treatment evidence each have a role in your care.

Pharmacy & fulfillment

Listed dispensing pharmacy

Availability depends on your prescription and location. For pharmacy questions, contact our team.

California: the Board issued a cease-and-desist order for this pharmacy in May 2026. We have not verified a later resolution. Read the licensing details and contact support before starting an assessment.

Explore our pharmacy quality standards

A direct line for follow-up

Message your provider through the patient portal about dosing, side effects, your response or changes in your health. Contact AnthologyRX support for billing, shipment or portal-access help.

Patient portalPatient support
The Evidence

What the research shows

Pooled phase 3 analysis · 806 participants · 26 weeks

Visceral fat fell 15.4% against placebo across two randomized trials.

15.4%
treatment effect on visceral adipose tissue at 26 weeks
The detail

The two pivotal phase 3 trials were pooled and analyzed together. Across 806 participants, 543 receiving tesamorelin and 263 receiving placebo, visceral adipose tissue measured by CT changed by minus 24 plus or minus 41 square centimeters with tesamorelin against plus 2 plus or minus 35 with placebo at 26 weeks, a treatment effect of minus 15.4 percent. The clinical target was excess visceral fat that had developed in the setting of antiretroviral therapy. Tesamorelin was not being studied as a treatment for HIV.3

Pooled phase 3 analysis · subcutaneous fat

The same analysis found no measurable effect on subcutaneous fat.

P=0.08
abdominal subcutaneous adipose tissue, not statistically different
The detail

The same pooled analysis measured abdominal subcutaneous adipose tissue separately and found minus 2 plus or minus 32 square centimeters with tesamorelin against plus 2 plus or minus 29 with placebo, P equals 0.08, a treatment effect of minus 0.6 percent. The measurable effect was in the visceral compartment, not in the fat under the skin.3

Randomized controlled trial · 60 adults · 12 months

The same selective effect appeared outside the original study population.

60 adults
abdominal obesity with reduced growth hormone secretion
The detail

A separate randomized, double-blind, placebo-controlled study enrolled 60 adults with abdominal obesity and reduced growth hormone secretion, a population defined by neither HIV nor antiretroviral therapy. Over 12 months tesamorelin reduced visceral adipose tissue against placebo with a treatment effect of minus 35 square centimeters, 95 percent confidence interval minus 58 to minus 12, P equals 0.003, while abdominal subcutaneous adipose tissue did not change significantly at P equals 0.40.6

Randomized controlled trial · 61 participants · 12 months

A separate trial found a 4.1 point reduction in liver fat fraction.

4.1 points
absolute treatment effect on hepatic fat fraction over 12 months
The detail

A randomized, double-blind, multicentre trial enrolled 61 adults living with HIV who also had nonalcoholic fatty liver disease, defined by a hepatic fat fraction of at least 5 percent, and randomized them to tesamorelin or placebo for 12 months. The absolute treatment effect on hepatic fat fraction was minus 4.1 percentage points, 95 percent confidence interval minus 7.6 to minus 0.7, P equals 0.018. This was a liver fat study, not a study of tesamorelin as a treatment for HIV.5

What it does not show

Evidence boundary · effect size outside the pivotal population

The pivotal effect size should not be treated as universal.

Population matters
the exact effect size outside the pivotal population is not established
The detail

The 15.4 percent visceral fat treatment effect comes from the pooled phase 3 population, who had excess abdominal fat that developed in the setting of antiretroviral therapy. Separate randomized research in adults with abdominal obesity and reduced growth hormone secretion found a significant visceral fat reduction without a significant subcutaneous fat reduction. Together those support the finding beyond the original population, but they do not establish that every cause of visceral adiposity responds by the same magnitude.36

FDA-approved labeling · limitations of use

The approved labeling states it is weight neutral and not for weight loss.

Weight neutral
the approved labeling’s own description
The detail

The FDA-approved labeling states under limitations of use that the product is not indicated for weight loss management as it has a weight neutral effect. The pivotal trial data support that distinction. Tesamorelin changed visceral adipose tissue without functioning as a conventional weight loss medication. This is not a scale-first treatment.4

FDA-approved labeling · extension phase

Visceral fat returned after treatment was stopped.

22% and 16%
visceral fat increase after switching from tesamorelin to placebo
The detail

In the extension phases of the two pivotal studies, participants who had received tesamorelin for 26 weeks and were then switched to placebo saw visceral adipose tissue increase by 22 percent and 16 percent over the following 26 weeks, and IGF-1 moved back toward baseline. The measured effect in those studies depended on continued treatment.4

Evidence boundary · aging and longevity

The trials cited here did not study longevity.

Not studied
lifespan, healthspan, biological age or anti-aging efficacy
The detail

The clinical research evaluated visceral adipose tissue, lipids, liver fat, body composition, metabolic measures and safety. It did not establish tesamorelin as a longevity or anti-aging treatment.12356

  1. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor… J Clin Endocrinol Metab. 2010.DOI
  2. Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese… J Clin Endocrinol Metab. 2012.DOI
  3. Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a… Lancet HIV. 2019.DOI
  4. EGRIFTA WR (tesamorelin) for injection, for subcutaneous use. Full Prescribing Information. Theratechnologies Inc. Revised 03/2025.
  5. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with… N Engl J Med. 2007.DOI
  6. Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in… J Acquir Immune Defic Syndr. 2010.DOI
Important Safety Information

Do not use if you have

  • Disruption of the hypothalamic-pituitary axis from pituitary disease, surgery, head irradiation or significant head trauma
  • Active malignancy
  • Known hypersensitivity to tesamorelin
  • Pregnancy

Serious risks

  • Fluid retention presenting as edema, arthralgia and carpal tunnel syndrome
  • Glucose intolerance or diabetes mellitus. Elevated HbA1c meeting the diabetes threshold developed in 5 percent of treated participants against 1 percent on placebo
  • Malignancy considerations, because growth hormone is a growth factor
  • Increased mortality reported with pharmacologic growth hormone in acute critical illness
  • Hypersensitivity reactions including pruritus, erythema, flushing, urticaria and rash, which occurred in 4 percent

Commonly reported

  • Arthralgia
  • Injection site erythema
  • Injection site pruritus
  • Pain in extremity
  • Peripheral edema
  • Myalgia

Because it is an injection

  • Injection site reactions occurred in 25 percent of treated participants against 14 percent on placebo

Reported effects follow the growth hormone axis. This is a compounded preparation, which means it has not been reviewed by the FDA for safety, effectiveness, or quality. Tesamorelin stimulates growth hormone production and raises IGF-1, a growth factor, and the effects of prolonged elevations in IGF-1 are unknown, so IGF-1 is monitored during therapy and treatment is reconsidered if it stays persistently elevated. Glucose status is evaluated before treatment and monitored during therapy, and a participant with diabetes is monitored for development or worsening of retinopathy. The approved labeling also describes these risks. A licensed provider decides whether tesamorelin belongs in your plan, and a licensed 503A pharmacy prepares the compounded prescription only after that decision.

Questions

Asked and answered.

Explore

More in Metabolic.

AnthologyRX is a technology and care-coordination platform, not a licensed pharmacy or medical provider. Clinical services are provided by independent licensed providers affiliated with Arora Health & Aesthetics, LLC, subject to their individual clinical judgment. Medications are dispensed or compounded by licensed pharmacies, including licensed 503A compounding pharmacies. Compounded medications are not FDA-approved drug products and have not been evaluated by the FDA for safety, efficacy, or quality. Brand names, where shown, identify the reference product only; AnthologyRX is not affiliated with their manufacturers. Individual results vary. No outcome is guaranteed. AnthologyRX does not provide medical advice and does not treat, cure, or prevent any disease. All treatments are subject to provider evaluation and approval. Available in all 50 U.S. states; availability of specific medications and formats varies by state. FSA/HSA eligibility varies by plan. AnthologyRX is not a replacement for primary or emergency medical care. Product images are illustrative. Packaging may vary by pharmacy and prescription. © 2026 AnthologyRX. All rights reserved.

AnthologyRX
Find your treatment
Browse all treatments